Integra LifeSciences: Caruso holds 43,590 shares
The reported options are exercisable as to 25% on each of the first four anniversaries of their respective grant dates.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Integra LifeSciences Holdings Corp. (IART) lists direct holdings reported by Andrea B. Caruso, CVP & CHRO, on October 1, 2026: 43,590 common shares. Her listed non-qualified options to buy common stock cover 4,375 shares at an exercise price of $43.3900; 2,634 at $68.1000; 2,674 at $65.1100; 3,244 at $52.8700; 4,634 at $36.2200; and 6,650 at $23.9500.
Insider Trade Summary
7 transactions reported
Mixed
7 txns
Insider
Caruso Andrea B
Role
CVP & CHRO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Non- Qualified Stock Option (right to buy) F1 | -- | -- | -- |
| holding | Non- Qualified Stock Option (right to buy) F2 | -- | -- | -- |
| holding | Non- Qualified Stock Option (right to buy) F3 | -- | -- | -- |
| holding | Non- Qualified Stock Option (right to buy) F4 | -- | -- | -- |
| holding | Non- Qualified Stock Option (right to buy) F5 | -- | -- | -- |
| holding | Non- Qualified Stock Option (right to buy) F6 | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Non- Qualified Stock Option (right to buy) — 24,211 contracts (Direct);
Common Stock — 43,590 shares (Direct)
Footnotes (6)
- F1. Stock option granted pursuant to the Integra LifeSciences Holdings Fourth Amended and Restated 2003 Equity Incentive Plan, as amended, exercisable as to 25% on each of the first four anniversaries of the date of grant of March 13, 2020.
- F2. Stock option granted pursuant to the Integra LifeSciences Holdings Fourth Amended and Restated 2003 Equity Incentive Plan, as amended, exercisable as to 25% on each of the first four anniversaries of the date of grant of March 12, 2021.
- F3. Stock option granted pursuant to the Integra LifeSciences Holdings Fifth Amended and Restated 2003 Equity Incentive Plan, as amended, exercisable as to 25% on each of the first four anniversaries of the date of grant of March 11, 2022.
- F4. Stock option granted pursuant to the Integra LifeSciences Holdings Fifth Amended and Restated 2003 Equity Incentive Plan, as amended, exercisable as to 25% on each of the first four anniversaries of the date of grant of March 10, 2023.
- F5. Stock option granted pursuant to the Integra LifeSciences Holdings Fifth Amended and Restated 2003 Equity Incentive Plan, as amended, exercisable as to 25% on each of the first four anniversaries of the date of grant of March 11, 2024.
- F6. Stock option granted pursuant to the Integra LifeSciences Holdings Fifth Amended and Restated 2003 Equity Incentive Plan, as amended, exercisable as to 25% on each of the first four anniversaries of the date of grant of March 11, 2025.
Key Figures
Direct common shares: 43,590 shares
Option underlying shares and exercise price: 4,375 shares; $43.3900
Option underlying shares and exercise price: 2,634 shares; $68.1000
+4 more
7 metrics
Direct common shares
43,590 shares
Reported by Andrea B. Caruso on October 1, 2026
Option underlying shares and exercise price
4,375 shares; $43.3900
Expiration: March 13, 2028
Option underlying shares and exercise price
2,634 shares; $68.1000
Expiration: March 11, 2029
Option underlying shares and exercise price
2,674 shares; $65.1100
Expiration: March 11, 2030
Option underlying shares and exercise price
3,244 shares; $52.8700
Expiration: March 10, 2031
Option underlying shares and exercise price
4,634 shares; $36.2200
Expiration: March 11, 2032
Option underlying shares and exercise price
6,650 shares; $23.9500
Expiration: March 11, 2033
Key Terms
Non- Qualified Stock Option (right to buy), Fourth Amended and Restated 2003 Equity Incentive Plan, Fifth Amended and Restated 2003 Equity Incentive Plan
3 terms
Non- Qualified Stock Option (right to buy) financial
"Non- Qualified Stock Option (right to buy)"
Fourth Amended and Restated 2003 Equity Incentive Plan financial
"granted pursuant to the Integra LifeSciences Holdings Fourth Amended and Restated 2003 Equity Incentive Plan"
Fifth Amended and Restated 2003 Equity Incentive Plan financial
"granted pursuant to the Integra LifeSciences Holdings Fifth Amended and Restated 2003 Equity Incentive Plan"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When do Andrea B. Caruso's IART stock options expire?
The reported non-qualified options expire as follows: 4,375 underlying shares on March 13, 2028; 2,634 on March 11, 2029; 2,674 on March 11, 2030; 3,244 on March 10, 2031; 4,634 on March 11, 2032; and 6,650 on March 11, 2033.
How do Andrea B. Caruso's IART options become exercisable?
For each listed option award, the options are exercisable as to 25% on each of the first four anniversaries of the grant date. The grants are dated March 13, 2020; March 12, 2021; March 11, 2022; March 10, 2023; March 11, 2024; and March 11, 2025.
AI-generated analysis. How Rhea-AI works. Not financial advice.
